2022
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, RheumatoidCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedRheumatologySurveys and QuestionnairesConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regression
2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedRheumatic DiseasesRheumatologySARS-CoV-2Surveys and QuestionnairesVaccinationConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritis
2020
Capturing Patient‐Reported Outcomes During the COVID‐19 Pandemic: Development of the COVID‐19 Global Rheumatology Alliance Patient Experience Survey
Sirotich E, Dillingham S, Grainger R, Hausmann J, Robinson P, Yazdany J, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann J, Machado P, Costello W. Capturing Patient‐Reported Outcomes During the COVID‐19 Pandemic: Development of the COVID‐19 Global Rheumatology Alliance Patient Experience Survey. Arthritis Care & Research 2020, 72: 871-873. PMID: 32386125, PMCID: PMC7272930, DOI: 10.1002/acr.24257.Peer-Reviewed Original Research